Coherence Neuro raises a $45 million Series A for closed-loop cancer therapy

Coherence Neuro announced on October 21, 2026 a $45 million Series A co-led by Founders Fund and The OpenAI Startup Fund to develop read/write devices that track and treat cancer in real time. The funds go to a first chronic human trial in glioblastoma, an FDA breakthrough-device application and preclinical pancreatic cancer work. Company post.